UroMems

UroMems

Private
Eybens, Auvergne-Rhône-AlpesHealthcare & Life Scienceshttps://www.uromems.com

Last Round

Strategic

May 13, 2026

Total Funding Raised

$147.97M

Momentum Score

25 /100

Company Overview

UroMems is a medical device company specializing in the design, development, and commercialization of active implantable devices that enhance surgical treatments while minimizing side effects for patients.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Health IoT, Clinical Trials, Sensors

Business Model

B2B2C

Customer Profile

Hardware Sales

AI Layer

Non-AI

Keywords

artificial urinary sphincterAUSstress urinary incontinenceSUIsmart implantmedtechurologyactive implantable medical deviceMEMSfemtechincontinence treatmentbionic implanturogynecologyclinical trialsFDA approval

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

UroMems Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

UroMems Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
StrategicMay 13, 2026
Series CJun 25, 2024
Series B ExtensionApr 20, 2021
Series BMay 20, 2020
Series ANov 15, 2016
Grant
Nov 15, 2016

Key People

Founding team and executive leadership

Pierre Mozer

Chief Medical Officer (Co-Founder)

Founding Team

Hamid Lamraoui

CEO

Executive Team

Agnès Dimey

CFO

Executive Team

John Murphy

Chief Operating Officer

Executive Team

UroMems Investors

Notable investors and investment history

InvestorRounds
European Innovation CouncilSeries C
European Commission (Horizon Europe)Series C
Ajax HealthStrategic
Caisse d'EpargneSeries B
Banque PopulaireSeries B
BpifranceSeries A, Series B, Grant, Series B Extension, Series C
Supernova InvestSeries B, Series B Extension, Series C

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 13, 2026

    $60M round led by Ajax Health

  • Feb 17, 2026

    Expanding US presence for clinical evaluations.

UroMems Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

UroMems Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about UroMems's valuation, stock price, and market status.

Firmographic Details

HeadquartersEybens, Auvergne-Rhône-Alpes
Employee Range74
Year Founded2011
Last FundingMay 13, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.







Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.